Drug Profile
JNJ 64213175
Alternative Names: JNJ-64213175; RSV preFLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Vaccines and Prevention B.V
- Class Protein vaccines; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
Most Recent Events
- 16 Jan 2023 Janssen Vaccines and Prevention B.V terminates a phase-I/II trial in Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Spain, USA (IM) based on recent study data for JNJ 64400141 (NCT05327816) (Eudra2022-001015-14)
- 05 Oct 2022 Phase-I/II clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Spain (IM) (NCT05327816) (Eudra2022-001015-14)
- 27 May 2022 Phase-I development in Respiratory-syncytial-virus-infections(Combination therapy, In the elderly, Prevention, In adults) is still ongoing USA (NCT03502707)